

## COMPANY OVERVIEW

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focussing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson's disease (PD), Alzheimer's disease (AD) and other related neurodegenerative diseases.

## RECENT NEWS

**Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Results in a Mice Model of Parkinson's disease of One of Its Orally Administered Novel DJ-1 Protein Targeting Therapeutic Candidates at the XXV International Symposium on Medicinal Chemistry in Ljubljana, Slovenia**  
Jul 31 2018, 7:20 AM EDT

## STOCK OVERVIEW

Symbol	CTBO
Exchange	OTCQB
Market Cap	1.33m
Last Price	\$0.02478
52-Week Range	\$0.01 - \$0.15

## INVESTOR RELATIONS

Russo Partners LLC  
12 West 27th Street  
4th Floor  
New York, NY 10001  
T: (844) 200-CTBO  
[ir@cantabio.com](mailto:ir@cantabio.com)

## MANAGEMENT TEAM

**Gergely Tóth, Ph.D., M.B.A.**  
Founder, Chief Executive Officer

**Simon Peace, M.Sc., M.B.A., A.C.M.A.**  
Chief Financial Officer

**Thomas Sawyer, Ph.D., M.B.A.**  
Chief Operations Officer

## CANTABIO PHARMACEUTICALS INC.

1250 Oakmead Pkwy  
Sunnyvale, CA 94085  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.